FCA action sees four guilty in £1.4m Dubai medical investment scheme
Four individuals have been found guilty of duping investors, in the UK and abroad, out of £1.4m in a Dubai-connected medial investment after a 49-day-long court case held at London’s Southwark Crown Court.
In a criminal prosecution brought by the UK’s financial services regulator the Financial Conduct Authority (FCA), Samrat Bhandari and Dr Muhammad Aleem Mirza have been found guilty for their roles in operating an investment scheme which led to more than 300 investors losing a total of just over £1.4m.
A third defendant, Albene Mendy, was found not guilty. The trial at Southwark Crown Court lasted 49 days, with the jury’s verdicts being returned on 30 November.
At an earlier hearing, two further defendants, brothers Michael and Paul Moore, pleaded guilty to offences in relation to the same scheme.
The four defendants will be sentenced between 19 and 20 December at Southwark Crown Court.
The FCA said in a statement following the verdict that it was assisted in the investigation and prosecution by a number of other law enforcement and government agencies, including the City of London Police, as well as by a number of investors in the scheme.
In the case, the FCA said that for periods between February 2009 and early 2014, brokers cold-called investors, many of whom it said were vulnerable, retired individuals, and mis-sold them shares in Symbiosis Healthcare Plc (Symbiosis). Symbiosis was set up by Aleem Mirza, a medical doctor, to provide “healthcare solutions”.
Samrat Bhandari was a director of William Albert Securities Ltd (“WASL”), a UK company which acted as corporate advisors to Symbiosis and organised the selling of Symbiosis shares. Albene Mendy also worked for WASL. Michael and Paul Moore were brokers directly involved in selling shares in Symbiosis to investors.
Despite promises to investors of large profits, and extravagant claims about the investment opportunity through the operation and expansion of a network of medical clinics in Dubai and elsewhere, in reality the shares in the company were, in effect, worthless, the UK regulator said.
The total value of investments made was around £1.4m. Each of the four defendants played an instrumental role in the “systematic and prolonged misleading of investors”, helping to create a wholly misleading impression as to the value and prospects of Symbiosis.
This was accomplished through misleading investors directly, on the phone, in correspondence, and in person, at Annual General Meetings, as well as through creating and publishing written statements and promotional material by or on behalf of Symbiosis, the FCA said.